Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs.

The emergence of e-diarrhoea in HCC patients treated with sorafenib is an early predictor of dismal evolution under this therapy. Thus, prompt identification of these non-responders may be useful for an early switch to second-line therapies.